FDA approves fast track designation of new TKK1 therapy for ER+/HER2- advanced breast cancer
The investigational drug, CFI-402257, has earned the FDA’s attention due to promising preclinical results and is now being investigated in a phase 1 study. The FDA granted fast-track designation to CFI-402257 for the treatment of adult patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy, as …